IRONDisc Medicine, Inc.
$62.08+2.1% 1Y
$62.08
$55.9552 weeks$94.11
IRON in its own filings
Nothing in IRON's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
170
Events found in the filings · across 757 filings · the record starts in 2020
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 10, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 14, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountanthistorical
- 2021-02-11
- Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares
- 2021-02-05
- SEC comment-letter activity24 occurrences
- 2023-11-27
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 10, 2026On September 9, 2026, the Company announced initial results from the RESTORE-PV clinical trial of DISC-3405 in patients with PV. The Phase 2, multi-center, open-label RESTORE-PV trial enrolled 40 adult participants with PV, including 20 participants in Cohort A and 20 participants in Cohort B. In the trial, following …Regulation FD disclosure · Form 8-K
- Jul 30, 2026Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 30, 2026On June 25, 2026, Disc Medicine, Inc. (the “Company”) entered into a First Amendment to Loan Agreement (the “Amendment”) to the Loan and Security Agreement dated as of November 6, 2024 (as amended, the “Loan Agreement”) among the Company, the lender party thereto and Hercules Capital, Inc., as administrative agent and …Material agreement entered · Form 8-K
- May 5, 2026Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Feb 27, 2026On February 26, 2026, the board of directors of Disc Medicine, Inc. (the “Company”) approved, and management began implementing, a restructuring plan (the “Restructuring Plan”) to better align the Company’s workforce with its near-term strategic priorities following the receipt of a complete response letter from the …Exit or disposal costs (restructuring) · Form 8-K
- Feb 26, 2026Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Feb 17, 2026Bitopertin Regulatory Update February 2026.Regulation FD disclosure · press release
- Feb 13, 2026On February 13, 2026, the Company received a CRL from the FDA for the Company’s NDA for bitopertin as a treatment for patients with EPP.Regulation FD disclosure · Form 8-K
- Jan 12, 2026Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026.Earnings release · press release
- Dec 8, 2025On December 7, 2025, Disc Medicine, Inc. (the “Company”) held a previously-announced conference call and webcast to review the Company's data presented at the 67th American Society of Hematology (“ASH”) Annual Meeting and Exposition and the Company's operational plans.Other event · Form 8-K
- Nov 6, 2025Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks